The aim of this project was to study the immunomodulatory effects of IFN-α treatment in two unique CML patient populations: (1) patients in prolonged remission during IFN-α monotherapy and (2) patients in prolonged remission after IFN-α monotherapy discontinuation. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.